Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
October 31 2017 - 6:15PM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that
Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical
Officer, gave an oral presentation at the World Immunotherapy
Congress 2017 in Basel, Switzerland at 5.50pm CEST on October 31,
2017.
The presentation included the following information and
data:
- Overview of Lymphocyte Activation Gene-3 (LAG-3) and its
structural relationship to the other MHC class II ligand, CD4;
- Therapeutic potential of engaging (in cancer) or suppressing
(in auto-immune diseases) the human immune response by modulating
either LAG-3 or its ligand MHC class II;
- Overview of the unique structure of Prima’s lead product
candidate, eftilagimod alpha (LAG-3Ig or IMP321), as a MHC class II
agonist and antigen presenting cell activator; and
- Review of Prima’s ongoing oncology-focused clinical trials of
eftilagimod alpha (AIPAC, TACTI-mel and INSIGHT) including:
- Immune monitoring data from the run-in phase of the AIPAC
clinical trial showing robust infiltration of T cells around
tumor noduleswith some T cells infiltrating the nodules
following 13 eftilagimod alpha s.c. injections in a metastatic
breast cancer patient treated with paclitaxel weekly; and
- Three patients have been recruited for Stratum A (intratumoral
(i.t.)) and Stratum B (intraperitoneal (i.p.)) of the INSIGHT
clinical trial.
The TACTI-mel Phase 1 clinical trial, being undertaken in
Australia, is investigating the use of eftilagimod alpha in
combination with pembrolizumab (KEYTRUDA) in metastatic melanoma
patients. The patients eligible to participate in the TACTI-mel
Phase 1 clinical trial are those that have either had no response
or a suboptimal response to KEYTRUDA monotherapy as a first-line of
treatment.
New data in relation to the first and second patient cohort of
TACTI-mel will be presented at the Society for Immunotherapy of
Cancer (SITC) 2017 meeting on 10-12 November, as previously
announced.
A copy of Dr Triebel’s presentation slides presented at
the World Immunotherapy Congress 2017 is available on Prima’s
website in the Presentations section of the Investors tab at
http://primabiomed.com.au/investor/presentations.php
Prima BioMed Prima BioMed is listed on the
Australian Securities Exchange and on the NASDAQ in the US. For
further information please visit www.primabiomed.com.au.
For further information please
contact:
U.S. Investors:Jay Campbell, Vice President of
Business Development and Investor Relations, Prima Biomed+1 (917)
860-9404; jay.campbell@primabiomed.com.au
Matthew Beck, The Trout Group LLC+1 (646) 378-2933;
mbeck@troutgroup.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From May 2024 to Jun 2024
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Immutep Limited (NASDAQ): 0 recent articles
More News Articles